CERM-Magnetic Resonance Center, Università degli Studi di Firenze, via Luigi Sacconi 6, 50019, Sesto Fiorentino, Italy.
Dipartimento di Scienze Biomediche Sperimentali e Cliniche "Mario Serio", Università degli Studi di Firenze, Viale Morgagni 50, 50134, Florence, Italy.
Angew Chem Int Ed Engl. 2020 Apr 16;59(16):6535-6539. doi: 10.1002/anie.201913436. Epub 2020 Feb 25.
Structure-based drug development is often hampered by the lack of in vivo activity of promising compounds screened in vitro, due to low membrane permeability or poor intracellular binding selectivity. Herein, we show that ligand screening can be performed in living human cells by "intracellular protein-observed" NMR spectroscopy, without requiring enzymatic activity measurements or other cellular assays. Quantitative binding information is obtained by fast, inexpensive H NMR experiments, providing intracellular dose- and time-dependent ligand binding curves, from which kinetic and thermodynamic parameters linked to cell permeability and binding affinity and selectivity are obtained. The approach was applied to carbonic anhydrase and, in principle, can be extended to any NMR-observable intracellular target. The results obtained are directly related to the potency of candidate drugs, that is, the required dose. The application of this approach at an early stage of the drug design pipeline could greatly increase the low success rate of modern drug development.
基于结构的药物开发常常受到阻碍,因为在体外筛选出有前途的化合物在体内往往没有活性,这是由于其低膜通透性或较差的细胞内结合选择性。在此,我们展示了可以通过“细胞内蛋白质观察”NMR 光谱在活的人细胞中进行配体筛选,而无需进行酶活性测量或其他细胞测定。通过快速、廉价的 H NMR 实验获得定量结合信息,提供细胞内剂量和时间依赖性配体结合曲线,从中获得与细胞通透性以及结合亲和力和选择性相关的动力学和热力学参数。该方法已应用于碳酸酐酶,并且原则上可以扩展到任何可通过 NMR 观察到的细胞内靶标。所得到的结果与候选药物的效力直接相关,即所需的剂量。在药物设计管道的早期应用这种方法可以大大提高现代药物开发的低成功率。